Loading...
Market
What will be the percentage increase in median lifespan in initial human trials of anti-IL-11 therapy by end of 2025?
2
Resolution / Starting Odds
0%-10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Peer-reviewed medical journals and clinical trial databases
Story
Study Shows Anti-IL-11 Therapy Extends Male Mouse Lifespan by 22.5%, Female by 25%
Jul 17, 2024, 04:20 PM
A recent study published in Nature has found that inhibiting the pro-inflammatory cytokine interleukin-11 (IL-11) can extend the lifespan of mice by up to 25%. The research demonstrated that both genetic deletion and an anti-IL-11 drug were effective in increasing the lifespans of laboratory mice. The treated mice exhibited fewer age-related health problems and maintained a more youthful appearance, earning them the nickname 'supermodel grannies' in the lab. The median lifespan of male mice increased by 22.5% and female mice by 25%. These findings are significant as anti-IL-11 therapies are already undergoing human clinical trials, raising hopes for potential applications in slowing human ageing.
View original story
Similar markets
0-10% • 25%
11-20% • 25%
21-30% • 25%
More than 30% • 25%
Lifespan Extension • 25%
Cancer Reduction • 25%
Gray Hair Reduction • 25%
Other • 25%
Yes • 50%
No • 50%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Approved • 25%
Increased lifespan • 25%
Improved healthspan • 25%
Reduced inflammation • 25%
Other • 25%
Yes • 50%
No • 50%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by another regulatory body • 25%
Not approved by any major regulatory body • 25%
Less than 50 months • 25%
50-60 months • 25%
60-70 months • 25%
More than 70 months • 25%